HemaQuest Pharmaceuticals, the developer of new treatments for blood diseases, has named John Longenecker as its new CEO, replacing Ron Berenson, according to a report in TechFlash. Longenecker was formerly the CEO of San Diego-based Favrille, the developer of an immune boosting therapy for cancer. HemaQuest will now likely have offices in San Diego and Seattle, Longenecker said in an e-mail to TechFlash. HemaQuest most recently made news when it closed on a $16 million financing round in July.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
